ArticleJournal for immunotherapy of cancer2026
Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL.
Kexin Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.